IDEA reports results from a prospective 3 years phase III study of Diractin (ketoprofen in Transfersome gel)

IDEA reports results from a prospective 3 years phase III study of Diractin (ketoprofen in Transfersome gel)
Munich, Germany – April 2, 2009. IDEA AG today announced positive results of a long-term, open-label, Phase III study in joint-pain, musculoskeletal pain (including lower back pain), stiffness, or soft tissue inflammation, presented at the 9th… (Source: Drugs.com - Clinical Trials)

Back Pain Treatment

Every year, 100’s of Millions of people suffer from back pain. The condition is extremely common and one of the leading reasons why people seek medical care. Read more

Back Pain Relief

Back pain is second only to headache as the most common neurological ailments in the world. Additionally, a 2002 study showed that back pain is one of the leading reasons why people visit the clinic and miss work. Read more